The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Castellanos Elaine since 2018.
This trader's CIK number is 1662520.
At the time of last reporting, Castellanos Elaine was the VP, Chief Accounting Officer of Reata Pharmaceuticals Inc. (stock ticker symbol RETA).
Also see all insider trading activities at Reata Pharmaceuticals Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2021 | RETA | 0 | $0 | 20,000 | $2,674,411 | 0 | $0 |
| 2020 | RETA | 0 | $0 | 7,500 | $1,292,650 | 0 | $0 |
| 2019 | RETA | 0 | $0 | 36,588 | $5,248,836 | 0 | $0 |
| 2018 | RETA | 0 | $0 | 7,336 | $375,163 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-06-07 | RETA | Sale | 1,546 | 146.82 | 226,977 |
| 2021-06-09 | RETA | Sale | 8,454 | 142.18 | 1,201,964 |
| 2021-05-26 | RETA | Sale | 10,000 | 124.55 | 1,245,470 |
| 2020-11-12 | RETA | Sale | 3,500 | 176.02 | 616,070 |
| 2020-06-01 | RETA | Sale | 2,000 | 143.97 | 287,940 |
| 2020-03-02 | RETA | Sale | 2,000 | 194.32 | 388,640 |
| 2019-12-02 | RETA | Sale | 2,000 | 194.24 | 388,480 |
| 2019-10-28 | RETA | Sale | 4,000 | 200.00 | 800,000 |
| 2019-10-25 | RETA | Sale | 2,000 | 190.00 | 380,000 |
| 2019-10-18 | RETA | Sale | 2,000 | 170.00 | 340,000 |
| 2019-10-15 | RETA | Sale | 14,000 | 152.76 | 2,138,640 |
| 2019-10-14 | RETA | Sale | 3,000 | 105.00 | 315,000 |
| 2019-09-06 | RETA | Sale | 2,000 | 85.00 | 170,000 |
| 2019-06-03 | RETA | Sale | 2,000 | 85.20 | 170,400 |
| 2019-04-08 | RETA | Sale | 2,000 | 90.17 | 180,340 |
| 2019-03-05 | RETA | Sale | 3,588 | 102.00 | 365,976 |
| 2018-07-23 | RETA | Sale | 7,336 | 51.14 | 375,163 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Castellanos Elaine (VP, Chief Accounting Officer of Reata Pharmaceuticals Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.